StaClear® Syringes Showcases FDA-Cleared For Intravitreal Injection at ASRS2026

Jul 7

RALEIGH, N.C., June 30, 2026 — StaClear®, Inc. will showcase its FDA-cleared syringes for intravitreal use at the 2026 American Society of Retina Specialists (ASRS) Annual Meeting in Montréal. “Retina specialists work hard to earn the right to perform one of medicine’s most precise procedures,” said Vinay Sakhrani, CEO of StaClear, Inc. “We believe the syringe they use to inject into the eye should earn that right, too.”

Developed with support from the National Eye Institute (NEI-NIH) and designed specifically for intravitreal injection, StaClear’s features include easy-to-read dose markings, smooth plunger glide and clear visibility of drug contents in the syringe barrel which is favored by retina specialists. Each lot of syringes is tested for compliance to USP 789 particulate standards.

StaClear’s portfolio includes Luer Lock, Luer Slip, and Attached Needle configurations, available in both unit packs and bulk trays, designed to support both retina practices and ophthalmic compounding pharmacies.

StaClear is manufactured under ISO 13485 and MDSAP certified quality systems and has obtained the CE Marking. It is available in the United States, Canada, Australia, New Zealand, and the European Union.

Visit StaClear at Booth #208 to meet the team, and why it has quickly become the gold standard in intravitreal injection.

About StaClear®

StaClear®, Inc. develops ophthalmic syringes engineered exclusively for intravitreal use. Focused solely on ophthalmic drug delivery, StaClear is on a mission to make intravitreal injection safer – one syringe at a time.

StaClear®, Inc.

7250 ACC Blvd. • Raleigh, NC 27617 USA

https://staclear.com • +1 (919) 838-6716 • info@staclear.com